• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • COVID-19
  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • Artificial Intelligence
    • Blockchain
    • Mobile Health
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Benchling Launches New RNA Capabilities to Accelerate Drug Discovery

by Jasmine Pennic 06/22/2021 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print
Benchling Launches New Products for Research & Biotech Startups to Accelerate Life Sciences Innovation

What You Should Know:

– Benchling, the leading life sciences cloud, today announced the launch of RNA Therapeutics R&D, a new digital solution that allows scientists to design, analyze, and develop complex RNA therapeutics in a unified cloud platform for the first time.

– More than 1,000 R&D organizations/customers can now accelerate collaboration, speed, and simplicity for RNA research via Benchling — an important advance for biotech. 

Biopharmaceutical R&D teams can use Benchling to collaborate across biology and chemistry workflows to support their collective efforts on this hybrid modality. These teams can work faster and improve their overall success rate by unifying traditionally siloed tasks and phases in one cloud-based solution. For the first time, scientists can design chemically modified oligonucleotides with ease, centralize experimental context and results, standardize on syntax, and collaborate with teammates more effectively on a single platform.

Scientists using Benchling can now:

– Create complex oligonucleotides with ease and contextualized experimental insights: Benchling saves researchers from having to repeatedly create their RNA from the atomic-level up. The visualization capabilities with Benchling’s HELM editor are built for oligo-level editing with the ability to zoom in and out on specific areas for modification. Experimental data is contextualized within Benchling’s solution, making high-quality data actionable throughout the oligo design process.

– Standardize data and simplify collaboration to accelerate the entire RNA therapeutic lifecycle: Benchling’s monomer library helps researchers quickly search and customize the most common base monomers. The embedded HELM notation support standardizes complex biomolecule representation so multidisciplinary teams can all access, understand, and contribute to the molecule’s ongoing development. The robust, integrated platform easily registers or creates oligos with uniqueness checks to save time and prevent redundant work.

Why It Matters

RNA has become a household name thanks to the successful development of mRNA-powered COVID-19 vaccines, and the category is exploding with more than 1,300 drugs in the pipeline. RNA is extremely complex — and teams just haven’t had the right tools to manage those elaborate datasets across multiple, often large and complicated organizations. Benchling is taking aim at that paralyzing complexity with a cloud platform tailored to RNA — helping biopharmaceutical teams get to world-changing breakthroughs (like Moderna/Pfizer) faster.

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Benchling, Drug Discovery

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Knowledge Hub

 How Top Health Plans Use AI to Save Money and Work Smarter How Top Health Plans Use AI to Save Money and Work Smarter

 How to Build Hybrid Care Models Around Remote Patient Monitoring How to Build Hybrid Care Models Around Remote Patient Monitoring

Trending

Metriport Launches Open-Source API to Instantly Pull Medical Records from Any EHR

Metriport Launches Open-Source API to Instantly Pull Medical Records from Any EHR

Nearly Half Of Consumers Report Their Healing has Been Directly Impacted by Difficulty Paying Medical Bills

Consumers Cite Healthcare Affordability as Biggest Concern to Paying Medical Bills

Mayo Clinic, GE HealthCare, Partner on Medical Imaging and Theranostics Innovation

Roundups: 16 Recent Strategic Digital Health Partnerships

How Telehealth Can Combat Clinician Burnout

How Telehealth Can Combat Clinician Burnout

Q/A: DocStation CEO Shares How AI Will Help Pharmacies Use the DIR Fee Changes to Their Advantage

Q/A: DocStation CEO Shares How AI Will Help Pharmacies Use the DIR Fee Changes to Their Advantage

Debunking Myths About Virtual Care to Drive Health Equity

Debunking 3 Myths About Virtual Care to Drive Health Equity

Provider AI Strategy Moves From The IT Dept. To The C-Suite

Notable Launches ChatGPT-Like Assistant for Patients

Notable Launches ChatGPT-Like Assistant for Patients

Intermountain to Replace Cerner with Epic Enterprise EHR by 2025

Intermountain to Replace Cerner with Epic Enterprise EHR by 2025

M&A: PE Firm Acquires NextGen Healthcare EHR for $1.8B

M&A: NextGen Healthcare EHR Acquired by PE Firm for $1.8B

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • 2023 Editorial Calendar
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2023. HIT Consultant Media. All Rights Reserved. Privacy Policy |